PDF(Pubmed)
Abstract：
Chronic Kidney Disease (CKD) has emerged as a global healthcare challenge affecting a significant portion of the world\'s population. This comprehensive narrative review delves into the intricate relationship between CKD and cardiovascular disease (CVD). CKD is characterized by kidney damage persisting for at least three months, often with or without a decline in glomerular filtration rate (GFR). It is closely linked with CVD, as individuals with CKD face a high risk of cardiovascular events, making cardiovascular-associated mortality a significant concern in advanced CKD stages. The review emphasizes the importance of precise risk assessment using biomarkers, advanced imaging, and tailored medication strategies to mitigate cardiovascular risks in CKD patients. Lifestyle modifications, early intervention, and patient-centered care are crucial in managing both conditions. Challenges in awareness and recognition of CKD and the need for comprehensive interdisciplinary care are highlighted. Recent advances in research offer promising therapies, such as SGLT2 inhibitors, MRAs, GLP-1R agonists, and selective endothelin receptor antagonists. Stem cell-based therapies, gene editing, and regenerative approaches are under investigation. Patient-physician \"risk discussions\" and tailored risk assessments are essential for improving patient outcomes. In conclusion, the review underscores the complexity of the interconnected CKD and cardiovascular health domains. Ongoing research, innovative therapies, and personalized healthcare will be instrumental in addressing the challenges, reducing the disease burden, and enhancing well-being for individuals facing CKD and cardiovascular issues. Recognizing the intricate connections between these conditions is imperative for healthcare providers, policymakers, and researchers as they seek to improve the quality of care and outcomes for affected individuals.
摘要：
慢性肾脏病（CKD）已成为全球医疗保健挑战，影响了世界上很大一部分人口。这篇全面的叙述性综述探讨了CKD与心血管疾病（CVD）之间的复杂关系。CKD的特点是肾脏损害持续至少三个月，通常有或没有肾小球滤过率（GFR）下降。它与CVD密切相关，由于CKD患者面临心血管事件的高风险，使心血管相关死亡率在晚期CKD阶段成为一个重要问题。该综述强调了使用生物标志物进行精确风险评估的重要性，先进的成像，和量身定制的药物策略，以减轻CKD患者的心血管风险。生活方式的修改，早期干预,以患者为中心的护理在管理这两种情况下都至关重要。强调了对CKD的认识和认识以及对全面跨学科护理的需求方面的挑战。研究的最新进展提供了有希望的治疗方法，如SGLT2抑制剂，MRA,GLP-1R激动剂,和选择性内皮素受体拮抗剂。干细胞疗法,基因编辑,再生方法正在调查中。患者-医生“风险讨论”和量身定制的风险评估对于改善患者预后至关重要。总之,该综述强调了相互关联的CKD和心血管健康领域的复杂性.正在进行的研究，创新疗法,个性化医疗保健将有助于应对挑战，减轻疾病负担,并提高面临CKD和心血管问题的个人的福祉。认识到这些条件之间的复杂联系对于医疗保健提供者来说是必不可少的，政策制定者，和研究人员，因为他们寻求提高护理质量和结果为受影响的个人。
